Ocular Therapeutix, Inc.

Quick facts

Marketed products

• Dexamethasone, 0.4mg

Phase 3 pipeline

• Dextenza Ophthalmic Insert · Ophthalmology
  Dextenza is a corticosteroid-eluting ophthalmic insert that delivers dexamethasone directly to ocular tissues to reduce inflammation and pain following eye surgery.
• Ophthalmic Insert · Ophthalmology
  An ophthalmic insert that delivers medication directly to the eye to treat ocular surface disease and inflammation.
• OTX-TKI · Ophthalmology
  OTX-TKI is a tyrosine kinase inhibitor designed for topical ocular delivery to treat eye surface diseases.
• OTX-TKI (axitinib implant) · Oncology
  OTX-TKI (axitinib implant) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors.
• Punctum Plug · Ophthalmology
  Punctum Plug is a biodegradable collagen shield used to treat punctal occlusion.

Phase 2 pipeline

• Collagen Punctal Plug
• Controlled Insertion
• OTX-DED
• OTX-TP

Phase 1 pipeline

• OTX-CSI
• OTX-TIC

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Ocular Therapeutix, Inc. portfolio CI brief
• Ocular Therapeutix, Inc. pipeline updates RSS